##plugins.themes.healthSciences.article.supplementaryFiles##
Keywords
Enzyme Deficiency
Lysosomal Storage Diseases
Sequencing, Variants (DeCS)
Gaucher Disease Biología Computacional
Secuenciación
Deficiencia enzimática
Enfermedad de Gaucher
Enfermedades por Almacenamiento Lisosomal
Variantes (DeCS)
How to Cite
Abstract
Introduction:Gaucher’s disease (EG) is an autosomal recessive genetic disorder, caused by a deficiency of the acid B-Glucocerebrosidase (GBA) enzyme. In Colombia, a prevalence of 1: 266.441 inhabitants have been estimated. However, the country does not have exact data on the incidence, prevalence and population burden of this disease. Objective: molecularly characterize the variants found in the GBA gene present in patients from the Southwest of Colombia with Gaucher disease. Material and methods: 19 patients were included in the study, 57,8% male, with an age range between 4 and 71 years, clinically and enzymatically diagnosed with GD. A molecular analysis of the GBA gene was performed and the variants were subsequently searched in different population and clinical databases; In addition, a bioinformatic analysis was performed to evaluate the possible impact of the variants of interest on the structure and functionality of the protein. Results: 14/19 homozygous patients were found; 4/19 compound heterozygotes and 1/19 heterozygotes). The presence of 7 variants coding for 8 different genotypes was reported. The most frequent genotype was p.Asn409Ser/p.Asn409Ser (36%). Of the 7 variants found, it was reported that specifically p. Asn409Ser (10/23 alleles) and p.Leu483Pro (3/23 alleles) and p.Lys237Glu (3/23 alleles), are present in 69,5% of the alleles. All the variants presented a pathogenic clinical significance. Conclusion: This work contributes to the establishment of the molecular bases of GD in patients from the Southwest of Colombia, allowing a genotype-endotype-phenotype correlation to be carried out. Likewise, it is determined that diagnostic algorithms that include molecular analysis and bioinformatic predictive tools allow improving the diagnosis, treatment and prognosis of patients affected by GD, generating a positive impact on the follow-up of those affected, hand in hand with correct genetic counseling and carrier studies.
References
Nguyen Y, Stirnemann J, Belmatoug N (2019). Gaucher disease: A review. Rev Med Interne; 18:31185-8
Sun A. Lysosomal storage disease overview (2018). Ann Transl Med..; 6(24): 476 6(24): 6-12
https://doi.org/10.21037/atm.2018.11.39
Mehta A (2006). Epidemiology and natural history of Gaucher's disease. Eur J Intern Med; 17 Suppl:S2-5.
https://doi.org/10.1016/j.ejim.2006.07.005
Nalysnyk L, Rotella., Simeone J, Hamed A, Weinreb N. (2017). Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology; 22(2): 65-73.
https://doi.org/10.1080/10245332.2016.1240391
ORPHANET. Enfermedad de Gaucher. Orphanet. [Internet]. [Consultado 12 Marzo 2019].Disponible en: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=ES&Expert=355
ADRES. Análisis De Los Recobros Correspondientes A Los Principios Activos Imiglucerasa, Miglustato, Velaglucerasa Y Taliglucerasa Medicamentos Para La Enfermedad De Gaucher. 2017. [Internet]. [Consultado:13 de marzo 2019]. Disponible en : https://www.adres.gov.co/La-Entidad/Publicaciones/Post/5993/An%C3%A1lisis-de-los-recobros-correspondientes-a-los-principios-activos-Imiglucerasa-Miglustato-Velaglucerasa-y-Taliglucerasa-medicamentos-para-la-enfermedad-de-Gaucher
Von Rossum A, Holsopple M. (2016) Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options. Hospital Pharmacy; 51(7): 553-563
https://doi.org/10.1310/hpj5107-553
Lavaut K, Núñez A, Nordet I, González A, Svarch, E, Machín S et al. (2010) Aspectos clínicos, bioquímicos, moleculares y tratamiento de 2 pacientes con enfermedad de Gaucher. Rev Cubana Hematol Inmunol Hemoter; 26(1), 54
Colquicocha-Murillo M, Cucho-Jurado J, Eyzaguirre-Zapata R, Manassero-Morales G, Moreno-Larrea M, Salas K et al (2015). Guía para diagnóstico y tratamiento de la Enfermedad de Gaucher. Rev Med Hered; 26 (2)103-121
https://doi.org/10.20453/rmh.v26i2.2447
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med; 17(5):405-424. https://doi.org/10.1038/gim.2015.30
https://doi.org/10.1038/gim.2015.30
Beutler E, Gelbart T, Scott CR. (2005) Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis; 35(3):355- 364.
https://doi.org/10.1016/j.bcmd.2005.07.005
Acanda de la Rocha A. (2012). Aspectos bioquímicos, genéticos y comorbilidades de la enfermedad de Gaucher, diagnóstico molecular en Cuba. Rev Cubana Genet Comunit; 6(1):8-19
Hruska KS, LaMarca ME, Scott CR, Sidransky E (2006). Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat; 29(5):567-588
https://doi.org/10.1002/humu.20676
Sheth J, Bhavsar R, Mistri M, Pancholi D, Bavdekar A, Dalal A, et al. (2019). Gaucher disease: single gene molecular characterization of one-hundred Indian patients reveals novel variants and the most prevalent mutation. BMC medical genetics; 20(1), 31. https://doi.org/10.1186/s12881-019-0759-1
https://doi.org/10.1186/s12881-019-0759-1
Hruska KS, LaMarca ME, Scott CR, Sidransky E (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat; 29(5):567-583
https://doi.org/10.1002/humu.20676
Schnabel D, Schroder M, Sandhoff K. (1991). Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease. FEBS Lett.;284 (1):57-59
https://doi.org/10.1016/0014-5793(91)80760-Z
Martinez-Arias R, Comas D, Mateu E, Bertranpetit J (2001). Glucocerebrosidase pseudogene variation and Gaucher disease: recognizing pseudogene tracts in GBA alleles. Hum Mutat.; 17(3):191-198
https://doi.org/10.1002/humu.4
Tsuji S, Choudary PV, Martin BM, Stubblefield BK, el alcalde JA, Barranger JA, et al. (1987) A Mutation in the Human Glucocerebrosidase Gene in Neuronopathic Gaucher's Disease. N Engl J Med.; 316 (10): 570-575.
https://doi.org/10.1056/NEJM198703053161002
Drugan C, Procopciuc L, Jebeleanu G, Grigorescu-Sido P, Dussau J, Poenaru L, et al. (2002). Enfermedad de Gaucher en pacientes rumanos: incidencia de las mutaciones y manifestaciones fenotípicas más comunes. Eur J Hum Genet. ; 10 (9): 511-515.
https://doi.org/10.1038/sj.ejhg.5200845
Riboldi GM, & Di Fonzo AB. (2019). GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells; 8(4): 364. http://doi.org/10.3390/cells8040364
https://doi.org/10.3390/cells8040364
López Reyes I, Esperón Álvarez AA, Lavaut Sánchez K, Puerta Díaz A, Santos González EN, Rubio González T, et al (2019) Caracterización molecular del gen GBA en pacientes cubanos con enfermedad de Gaucher. Rev gen com; 11(1)
Pomponio RJ, Cabrera-Salazar MA, Echeverri OY, Miller G, Barrera LA (2005). Guacher disease in Colombia: mutation identification and comparison to other Hispanic populations. Mol Genet Metab; 86: 466-72
https://doi.org/10.1016/j.ymgme.2005.07.026
Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C,et al . (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci; 17;18(2). http://doi.org/10.3390/ijms18020441.
https://doi.org/10.3390/ijms18020441
Goker-Alpan O, Hruska K, Orvisky E, Kishanani P, Stubblefield BK, Schiffmann R et al (2005). Divergent phenotypes in Gaucher disease implicate the role of modifiers.J Med Genet; 42(6):e 37
https://doi.org/10.1136/jmg.2004.028019
Kumar K, Ramirez A, Gobel A, Kresojevic N, Svetel M, Lohmann K, et al (2013). Glucocerebrosidase mutations in a Serbian Parkinson's disease population. European Journal of Neurology., 20: 402-405
https://doi.org/10.1111/j.1468-1331.2012.03817.x
Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, et al (2016). Specifically, neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Ann Neurol; 80(5), 674-685. https://doi.org/10.1002/ana.24781
https://doi.org/10.1002/ana.24781
Paciottia S, Persichettia E , Pagliardini S, Deganutoc M, Rosano C et al. (2012). First pilot newborn screening for four lysosomal storage diseases in an Italian region: Identification and analysis of a putative causative mutation in the GBA gene Clinica Chimica Acta; 413: 23-24, 20
https://doi.org/10.1016/j.cca.2012.07.011
Goker-Alpan O, Schiffmann R, Park J, Stubblefield B, Tayebi N, Sidransky E. (2003). Phenotypic continuum in neuronopathic gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr.; 143(2) 273-276
https://doi.org/10.1067/S0022-3476(03)00302-0
Chan A, Holleran W, Ferguson T, Crumrine D, Goker-Alpan O, Schiffman R, et al. (2011). Skin ultrastructural findings in type 2 Gaucher disease: Diagnostic implications. Mol Genet Metab; 104 (4): 631-636
https://doi.org/10.1016/j.ymgme.2011.09.008
Z. Kato, S. Fukuda, S. Tomatsu, H. Vega, T. Yasunaga, A. Yamagishi, et al.(1997). A novel common missense mutation G301C in the N-acetylgalactosamine-6-sulfate sulfatase gene in mucopolysaccharidosis IVA, Hum. Genet. 101 (1): 97-101
https://doi.org/10.1007/s004390050594
Moors, T.E., Paciotti, S., Ingrassia, A. et al. (2019) Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson's Disease and Dementia with Lewy Bodies. Mol Neurobiol 56, 1344-1355. https://doi.org/10.1007/s12035-018-1090-0
https://doi.org/10.1007/s12035-018-1090-0
Siebert M, Bock H, Michelin-Tirelli K, Coelho J, Giugliani R, Saraiva-Pereira ML. (2011). Novel Mutations in the Glucocerebrosidase Gene of Brazilian Patients with Gaucher Disease. JIMD R; 9:7-16. http://doi.org/10.1007/8904_2012_174
https://doi.org/10.1007/8904_2012_174
J.A. Ruskey, L. Greenbaum, Lé. Roncière, A. Alam, D. Spiegelman, C. Liong, O.A. et al (2018) Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. Eur J Med Genet; 62(1):65-69. http://doi.org/10.1016/j.ejmg.2018.05.005
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2020 REVISTA DE LA ASOCIACION COLOMBIANA DE CIENCIAS BIOLOGICAS